Palwa, Bohari M.
HRN: 26-46-30 Sex: MalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
12/31/2024
PIPERACILLIN + TAZOBACTAM 2.25G (VIAL)
12/31/2024
01/06/2025
IV
2.25g
Every 6hours
Infected Wound
Waiting Final Action
Indication: Empiric Type of Infection: Skin & Soft Tissue Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes